-
Je něco špatně v tomto záznamu ?
Novel Inhibitors of Acetyl- and Butyrylcholinesterase Derived from Benzohydrazides: Synthesis, Evaluation and Docking Study
NH. Houngbedji, Š. Štěpánková, V. Pflégr, K. Svrčková, M. Švarcová, J. Vinšová, M. Krátký
Status neindexováno Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Grantová podpora
20-19638Y
Czech Science Foundation
SVV 260 547
Charles University
CZ.02.1.01/0.0/0.0/16_019/0000841
ERDF
NLK
Directory of Open Access Journals
od 2009
Free Medical Journals
od 2009
PubMed Central
od 2004
Europe PubMed Central
od 2004
ProQuest Central
od 2004-01-01
Open Access Digital Library
od 2004-01-01
Open Access Digital Library
od 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2004
PubMed
37259322
DOI
10.3390/ph16020172
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
On the basis of previous reports, novel 2-benzoylhydrazine-1-carboxamides were designed as potential inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). Inhibitors of these enzymes have many clinical applications. 2-(Substituted benzoyl)hydrazine-1-carboxamides decorated with N-methyl or tridecyl were prepared with three methods from commercially available or self-prepared hydrazides and isocyanates. For methyl derivatives, N-succinimidyl N-methylcarbamate was used or methyl isocyanate was prepared via Curtius rearrangement. Tridecyl isocyanate was synthesized again via Curtius rearrangement or from triphosgene and tridecylamine. The compounds were evaluated for the inhibition of AChE and BChE using Ellman's spectrophotometric method. Most of the derivatives showed the dual inhibition of both enzymes with IC50 values of 44-100 μM for AChE and from 22 μM for BChE. In general, the carboxamides inhibited AChE more strongly. A large number of the compounds showed better or quite comparable inhibition of cholinesterases in vitro than that of the drug rivastigmine. Molecular docking was performed to investigate the possible conformation of the compounds and their interactions with target enzymes. In both AChE and BChE, the compounds occupied the enzyme active cavity, and, especially in the case of BChE, the compounds were placed in close proximity to the catalytic triad.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23010175
- 003
- CZ-PrNML
- 005
- 20230721095305.0
- 007
- ta
- 008
- 230707s2023 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/ph16020172 $2 doi
- 035 __
- $a (PubMed)37259322
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Houngbedji, Neto-Honorius $u Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic
- 245 10
- $a Novel Inhibitors of Acetyl- and Butyrylcholinesterase Derived from Benzohydrazides: Synthesis, Evaluation and Docking Study / $c NH. Houngbedji, Š. Štěpánková, V. Pflégr, K. Svrčková, M. Švarcová, J. Vinšová, M. Krátký
- 520 9_
- $a On the basis of previous reports, novel 2-benzoylhydrazine-1-carboxamides were designed as potential inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). Inhibitors of these enzymes have many clinical applications. 2-(Substituted benzoyl)hydrazine-1-carboxamides decorated with N-methyl or tridecyl were prepared with three methods from commercially available or self-prepared hydrazides and isocyanates. For methyl derivatives, N-succinimidyl N-methylcarbamate was used or methyl isocyanate was prepared via Curtius rearrangement. Tridecyl isocyanate was synthesized again via Curtius rearrangement or from triphosgene and tridecylamine. The compounds were evaluated for the inhibition of AChE and BChE using Ellman's spectrophotometric method. Most of the derivatives showed the dual inhibition of both enzymes with IC50 values of 44-100 μM for AChE and from 22 μM for BChE. In general, the carboxamides inhibited AChE more strongly. A large number of the compounds showed better or quite comparable inhibition of cholinesterases in vitro than that of the drug rivastigmine. Molecular docking was performed to investigate the possible conformation of the compounds and their interactions with target enzymes. In both AChE and BChE, the compounds occupied the enzyme active cavity, and, especially in the case of BChE, the compounds were placed in close proximity to the catalytic triad.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Štěpánková, Šárka $u Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Studentská 573, 532 10 Pardubice, Czech Republic $1 https://orcid.org/0000000219695258 $7 xx0127227
- 700 1_
- $a Pflégr, Václav $u Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic $1 https://orcid.org/0000000299539334
- 700 1_
- $a Svrčková, Katarína $u Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Studentská 573, 532 10 Pardubice, Czech Republic $1 https://orcid.org/0000000169616151
- 700 1_
- $a Švarcová, Markéta $u Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic
- 700 1_
- $a Vinšová, Jarmila $u Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic
- 700 1_
- $a Krátký, Martin $u Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic $1 https://orcid.org/0000000246008409 $7 jo2017947786
- 773 0_
- $w MED00184066 $t Pharmaceuticals (Basel, Switzerland) $x 1424-8247 $g Roč. 16, č. 2 (2023)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37259322 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230707 $b ABA008
- 991 __
- $a 20230721095258 $b ABA008
- 999 __
- $a ok $b bmc $g 1958666 $s 1196439
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2023 $b 16 $c 2 $e 20230124 $i 1424-8247 $m Pharmaceuticals $n Pharmaceuticals (Basel) $x MED00184066
- GRA __
- $a 20-19638Y $p Czech Science Foundation
- GRA __
- $a SVV 260 547 $p Charles University
- GRA __
- $a CZ.02.1.01/0.0/0.0/16_019/0000841 $p ERDF
- LZP __
- $a Pubmed-20230707